Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Feb;124(2):210-5.
doi: 10.1016/j.ygyno.2011.10.002. Epub 2011 Nov 1.

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma

Andrea E Wahner Hendrickson  1 , Ann L Oberg, Gretchen Glaser, John K Camoriano, Prema P Peethambaram, Gerardo Colon-Otero, Charles Erlichman, S Percy Ivy, Scott H Kaufmann, Larry M Karnitz, Paul Haluska
Affiliations
Clinical Trial

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma

Andrea E Wahner Hendrickson et al. Gynecol Oncol. 2012 Feb.

Abstract

Objective: To evaluate the efficacy and biological effects of the gemcitabine/tanespimycin combination in patients with advanced ovarian and peritoneal cancer. To assess the effect of tanespimycin on tumor cells, levels of the chaperone proteins HSP90 and HSP70 were examined in peripheral blood mononuclear cells (PBMC) and paired tumor biopsy lysates.

Methods: Two-cohort phase II clinical trial. Patients were grouped according to prior gemcitabine therapy. All participants received tanespimycin 154 mg/m(2) on days 1 and 9 of cycle 1 and days 2 and 9 of subsequent cycles. Patients also received gemcitabine 750 mg/m(2) on day 8 of the first treatment cycle and days 1 and 8 of subsequent cycles.

Results: The tanespimycin/gemcitabine combination induced a partial response in 1 gemcitabine naïve patient and no partial responses in gemcitabine resistant patients. Stable disease was seen in 6 patients (2 gemcitabine naïve and 4 gemcitabine resistant). The most common toxicities were hematologic (anemia and neutropenia) as well as nausea and vomiting. Immunoblotting demonstrated limited upregulation of HSP70 but little or no change in levels of most client proteins in PBMC and paired tumor samples.

Conclusions: Although well tolerated, the tanespimycin/gemcitabine combination exhibited limited anticancer activity in patients with advanced epithelial ovarian and primary peritoneal carcinoma, perhaps because of failure to significantly downregulate the client proteins at clinically achievable exposures.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement

None of the authors have any conflicts of interest to disclose.

Figures

Figure 1
Figure 1
A, Overall survival of patients in Cohort 1 (N=12) and Cohort 2 (N=11) entered on this study. B, Progression-free survival of patients in Cohort 1 (N=12) and Cohort 2 (N=11) entered on this study.
Figure 2
Figure 2
Maximum severity adverse events experienced per patient that were possible, probably or definitely related to treatment on this study.
Figure 3
Figure 3
Effects of tanespimycin on client protein levels. A, after the indicated ovarian cancer cell lines were treated with diluent (0.1% DMSO) or tanespimycin at 30, 100, 300, or 1000 nM for 24 h, whole cell lysates were subjected to SDS-PAGE followed by immunoblotting for the indicated antigen. B, lysates prepared from PBMCs prior to therapy (odd numbered lanes) and 24 h after the first dose of tanespimycin (even numbered lanes) were subjected to immunoblotting for the indicated antigens. HSP90β or β-actin served as loading controls in these studies. C, whole cell lysates prepared from ovarian cancer biopsies harvested prior to therapy (lanes 1, 3 and 5) or from the same tumors 22–26 h after the day 1 dose of tanespimycin (lanes 2, 4 and 6) were subjected to SDS-PAGE followed by immunoblotting. Dashed line indicates remove of intervening unequally loaded samples from the blots. Number at left, migration of molecular weight markers (kDa). Graphs at right show quantitation of signals for selected client proteins before and after tanespimycin treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010;11:515–28. - PubMed
    1. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761–72. - PubMed
    1. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer. 2010;10:537–49. - PMC - PubMed
    1. Schnur RC, Corman ML, Gallaschun RJ, Cooper BA, Dee MF, Doty JL, Muzzi ML, Moyer JD, DiOrio CI, Barbacci EG, et al. Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives. J Med Chem. 1995;38:3806–12. - PubMed
    1. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol. 1998;42:273–9. - PubMed

Publication types

MeSH terms